SuanFarma-Header SuanFarma-Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter
×
FILTER:
filter Country
    filter News Type
      filter Company
        filter Product Type
          filter Deal Size

            Active Filter(s):

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Lead Product(s): EB005

            Therapeutic Area: Dermatology Product Name: EB005

            Highest Development Status: Discovery Product Type: Undisclosed

            Partner/Sponsor/Collaborator: GlaxoSmithKline

            Deal Size: $224.0 million Upfront Cash: Undisclosed

            Deal Type: Collaboration January 11, 2021

            Details:

            Eligo will receive an upfront payment and R&D funding to advance EB005, until preclinical proof of concept. If GSK exercises its option, GSK and Eligo will enter into a license and collaboration agreement to jointly continue the development of EB005 in acne.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Lead Product(s): Undisclosed

            Therapeutic Area: Dermatology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Undisclosed

            Partner/Sponsor/Collaborator: University of Dundee

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration October 08, 2020

            Details:

            The collaboration aim to develop a novel class of medicines that target and degrade disease-causing proteins. The novel mechanism of action of PROTACs generates the possibility to eliminate disease relevant targets that were difficult to tackle with conventional approaches.